Evaluation of the Pharmacokinetics and Renal Excretion of Simeprevir in Subjects with Renal Impairment
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Evaluation of the Pharmacokinetics and Renal Excretion of Simeprevir in Subjects with Renal Impairment
Authors
Keywords
-
Journal
Drugs in research & development
Volume 15, Issue 3, Pages 261-270
Publisher
Springer Nature
Online
2015-08-06
DOI
10.1007/s40268-015-0101-0
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Viral Hepatitis C Therapy: Pharmacokinetic and Pharmacodynamic Considerations
- (2014) Clara T. M. M. de Kanter et al. CLINICAL PHARMACOKINETICS
- Simeprevir With Peginterferon and Ribavirin Leads to High Rates of SVR in Patients With HCV Genotype 1 Who Relapsed After Previous Therapy: A Phase 3 Trial
- (2014) Xavier Forns et al. GASTROENTEROLOGY
- P1319 ONCE-DAILY SIMEPREVIR (TMC435) WITH PEGINTERFERON/RIBAVIRIN IN TREATMENT-NAIVE OR TREATMENT-EXPERIENCED CHRONIC HCV GENOTYPE 4-INFECTED PATIENTS: FINAL RESULTS OF A PHASE III TRIAL
- (2014) C. Moreno et al. JOURNAL OF HEPATOLOGY
- Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial
- (2014) Ira M Jacobson et al. LANCET
- Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial
- (2014) Michael Manns et al. LANCET
- Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study
- (2014) Eric Lawitz et al. LANCET
- Hepatitis C virus infection in end-stage renal disease and kidney transplantation
- (2014) Patrizia Burra et al. TRANSPLANT INTERNATIONAL
- Pegylated Interferon-α2a With or Without Low-Dose Ribavirin for Treatment-Naive Patients With Hepatitis C Virus Genotype 1 Receiving Hemodialysis
- (2013) Chen-Hua Liu et al. ANNALS OF INTERNAL MEDICINE
- Simeprevir Increases Rate of Sustained Virologic Response Among Treatment-Experienced Patients With HCV Genotype-1 Infection: A Phase IIb Trial
- (2013) Stefan Zeuzem et al. GASTROENTEROLOGY
- Telaprevir: pharmacokinetics and drug interactions
- (2012) Varun Garg et al. ANTIVIRAL THERAPY
- Single-Dose Pharmacokinetics of Boceprevir in Subjects with Impaired Hepatic or Renal Function
- (2012) Michelle Treitel et al. CLINICAL PHARMACOKINETICS
- An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases
- (2011) Marc G. Ghany et al. HEPATOLOGY
- Incidence of hepatitis C virus infection in patients with chronic kidney disease on conservative therapy
- (2011) Gioacchino Li Cavoli et al. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
- Pegylated interferon monotherapy of chronic hepatitis C in dialysis patients: Meta-analysis of clinical trials
- (2010) Fabrizio Fabrizi et al. JOURNAL OF MEDICAL VIROLOGY
- In Vitro Activity and Preclinical Profile of TMC435350, a Potent Hepatitis C Virus Protease Inhibitor
- (2009) T.-I Lin et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- The effect of chronic renal failure on drug metabolism and transport
- (2008) Albert W Dreisbach et al. Expert Opinion on Drug Metabolism & Toxicology
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started